Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025)
Historic FCF Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 29632.0%.
- Lyra Therapeutics' FCF Margin fell 212863600.0% to 29632.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3654.6%, marking a year-over-year increase of 91542600.0%. This contributed to the annual value of 4130.36% for FY2023, which is 9352800.0% down from last year.
- Per Lyra Therapeutics' latest filing, its FCF Margin stood at 29632.0% for Q3 2025, which was down 212863600.0% from 3601.09% recorded in Q2 2025.
- Lyra Therapeutics' 5-year FCF Margin high stood at 852.38% for Q4 2024, and its period low was 110836.36% during Q4 2022.
- Its 5-year average for FCF Margin is 16279.93%, with a median of 3876.83% in 2023.
- In the last 5 years, Lyra Therapeutics' FCF Margin crashed by -1062681000bps in 2022 and then surged by 972439000bps in 2023.
- Over the past 5 years, Lyra Therapeutics' FCF Margin (Quarter) stood at 4568.27% in 2021, then plummeted by -2326bps to 110836.36% in 2022, then surged by 88bps to 13592.47% in 2023, then surged by 106bps to 852.38% in 2024, then crashed by -3576bps to 29632.0% in 2025.
- Its FCF Margin stands at 29632.0% for Q3 2025, versus 3601.09% for Q2 2025 and 4831.69% for Q1 2025.